CC2 Cost of Preventable Adverse Drug Events in Emergency Department Patients  by Dominguez-Gil, A et al.
42






PATIENTS WITH CHRONIC BRONCHITIS
Rappenhoner B, Bachinger A, Rychlik R
Institute of Empirical Health Economics. Odenthal. Genmany
The socioeconomic value of prophylaxis of acute exacer-
bations in patients with chronic recurrent bronchitis with
N-acetylcysteine (NAC) in comparison to no prophylaxis
is the subject of this analysis. In the case of an exacerba-
tion, therapy with the antibiotic amoxicillin was pre-
sumed.
METHODS: This decision tree analysis is based on a
meta-analysis, which described the probability and the
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frequency of an exacerbation either in the case of prophy-
laxis with NAC or no prophylaxis. Three sensitivity anal-
yses have been carried out. To check the stability of the
results of this cost-utility-analysis, therapy with arnoxicil-
lin was replaced by the antibiotic doxycycline. The daily
costs of NAC, which have a considerable influence on the
direct costs, were also varied. Finally, the influence of the
probability of inpatient therapy was analyzed.
RESULTS: Documented over a period of one year, pro-
phylaxis with NAC resulted in direct costs of 438.42
DM, whereas no prophylaxis caused direct costs of
266.82 DM. On the basis of indirect costs, prophylaxis
with NAC caused costs of 2,177.36 DM and no prophy-
laxis caused costs of 2,569.42 DM. The result of project-
ing these costs for the estimated 122,830 patients with
chronic recurrent bronchitis in the Federal Republic of
Germany reveals a potential of savings of total costs of
approximately 27.1 million DM in the case of a change
from no prophylaxis to prophylaxis with NAC.
CONCLUSION: This decision tree analysis reveals that
prophylaxis with NAC causes higher direct costs but in
long term it reduces the indirect costs by reducing the
time off work.
CC2
COST OF PREVENTABLE ADVERSE DRUG
EVENTS IN EMERGENCY DEPARTMENT
PATIENTS
Dominguez-Gil A, Bajo A, Otero MJ, Garcia-Gutierrez JF
Hospital Universitario de Salamanca. Salamanca. Spain
1-4% of all visits to emergency rooms are due to adverse
drug events (ADEs), but data about preventability and
cost due to preventable ADEs in this setting are limited.
OBJECTIVE: To determine the incidence of ADEs associ-
ated with emergency department (ED) visits and subse-
quent hospital admissions; to assess their preventability
and to estimate the costs of preventable ADEs to our in-
stitution, a 750-bed university tertiary care center.
METHODS: All patients who visited the ED from Octo-
ber 1995 to March 1996 were prospectively evaluated.
Recorded data included: medical and medication history,
laboratory data, serum drug concentrations, ED proce-
dures, intervention therapy, and characteristics and out-
come of ADEs. Patients admitted as a result of the ADE
were followed to collect information of invasive and non
invasive procedures, therapy, length of stay, and intensive
care. Preventable ADEs were analyzed to identify the as-
sociated factors. A cost analysis was performed.
RESULTS: From a total of 33,975 visits to the ED, 766
(2.25%) were due to ADEs. A total of 336 (43.9%) ADEs
were assessed as preventable; these resulted in 121 hospital
admissions, 1,575 stays, 121 ICU days, and 15 deaths. Inap-
propiate dose prescribed and inadequate monitoring of drug
therapy accounted for 46% and 31 % of preventable ADEs;
17% preventable ADEs were due to automedication. The
estimated hospital annual cost for all ADEs was $1.42 mil-
lion and for preventable ADEs was almost $1 million.
Abstracts
CONCLUSIONS: Many ADES seen in ED patients are
preventable and contribute substantially to hospital costs.
At a time when much emphasis is put on the limitation of
health expenses, here is a domain where expense-cutting
could probably be done reasonably easily, while increas-
ing quality of care.
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MODELING SIDE EFFECT COSTS FROM
L1TERATURE·BASED DATA: STEROID·INDUCED
SIDE EFFECTS IN RENAL TRANSPLANTATION
Veenstra DL. Stergachis A, and SullivanSD
University of Washington School of Pharmacy, Seattle,
WA, USA
Assessing the economic impact of medication side effects
is critical for the accurate determination of the cost-effec-
tiveness of pharmaceuticals. It is often necessary to em-
ploy modeling techniques that utilize incidence rates that
are based on the literature.
OBJECTIVE: To present a calculation of the cost of ste-
roid-induced side effects in renal transplantation as an
example of a literature-based model and to discuss the as-
sumptions, techniques, and difficulties inherent in the
methodology.
METHODS: We estimated the incidence of adverse
events associated with steroids using evidence-based liter-
ature analyses. This evidence was used to construct a
Markov cost model for each side effect. Side effects in-
cluded in the analysis were hypertension (and its compli-
cations), post-transplant diabetes mellitus (PTDM), pe-
ripheral bone fractures, osteonecrosis of the hip, and
cataracts.
RESULTS: The side effect incidences reported in the liter-
ature vary, in part due to different definitions and follow-
up periods. Furthermore, data from randomized con-
trolled trials can be handicapped by low statistical power
to detect side effects and patient crossover or dropouts.
Confounding and bias are concerns in case-control and
cohort studies, and can complicate the determination of
attributable risk from cohort studies. Utilizing the inci-
dence data from the literature, the total 10-year dis-
counted cost for a 50-patient cohort was $266,000.
CONCLUSIONS: Extracting side effect incidence data
from the literature is a challenging but essential step in
modeling side effect costs. The variability in reported re-
sults should be ascertained, and assumptions requiring
clinical expertise are often required. We have demon-
strated the methodology and estimated the financial cost
of adverse events associated with steroids in renal trans-
plantation.
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COST-BENEFIT ANALYSIS OF RECOMBINANT
ERYTHROPOIETIN IN PREMATURE NEONATES
Wandstrat TL. Maxwell SR
West Virginia University, Charleston, WV, USA
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The use of recombinant human erythropoietin (rhEPO)
and intravenous (IV) iron was studied in a group of pre-
mature neonates.
OBJECTIVE: The study purpose was to conduct a cost-
benefit analysis of the use of rhEPO and IV iron to reduce
the need of erythrocyte transfusions (Ets) in premature
neonates.
METHODS: Neonates 24-30 weeks gestational age (GA)
were considered for admission into the study. Patients
were excluded if severe hemolytic or hepatic disease, or
renal failure were present. If caretakers did not consent to
rhEPO and IV iron therapy, the patients were followed as
controls. For patients who were given caretaker consent,
treatment included IV iron 1 mg/kg/day in hyperalimen-
tion or IV fluids and 400 U/kg/dose of IV rhEPO three
times per week for 4 weeks, initiated at days 1-5 of life.
There were 41 patients in the rhEPO group and 13 in the
control group recruited over 12 months.
RESULTS: The mean number of Ets performed in the
first 4 weeks of life were 2.8 ::'::: 2.5 for the control group
and 1.9 ::'::: 2.7 for the rhEPO group (p = 0.28). The direct
cost of providing rhEPO and IV iron to the 41 study pa-
tients was $8160.11 The direct cost of one Et in our insti-
tution is $235.05. No indirect costs (adverse effects) were
noted. The average reduction in Ets per patient was 0.9
and if extrapolated to 41 patients would have resulted in
cost savings (benefit) of $8673.34. The benefit to cost ra-
tio of this program was 1.1:1.
CONCLUSION: rhEPO and IV iron use was associated
with a reduction of Ets and proved cost beneficial in a
small group of premature neonates ~30 weeks GA.
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INCREMENTAL COST·EFFECTIVENESS
ANALYSIS COMPARING 4-LAYER BANDAGE
SYSTEM WITH AND WITHOUT APLIGRAFTM
FOR THE OUTPATIENT TREATMENT OF
VENOUS LEG ULCERS
Attard 0, MacNeil p2, Sibbald GR3, Torrance GW',\
Walker VI
'Innovus Research Inc., Burlington, Ontario, Canada;
2(Formerly) Novartis Pharmaceuticals Canada Inc., Dorval,
Quebec, Canada; 3University of Toronto, Toronto, Ontario,
Canada; 4McMaster University, Hamilton, Ontario, Canada
Apligraf'>' is a full thickness manufactured living skin
equivalent indicated for the treatment of venous leg ul-
cers (VLU).
OBJECTIVE: To undertake a model-based retrospective
cost-effectiveness analysis (CEA), from a societal and
health care perspective, of the outpatient treatment of
VLU with the 4-1ayer high-compression bandage system
with and without one application of Apligraf'?".
METHODS: Because no prospective head-to-head study
of this comparison had yet been undertaken, a computer-
based model was developed. The model represented the
clinical consequences of the two approaches (ulcers
healed, time to heal, ulcer recurrence, infections, compli-
